Logo

American Heart Association

  2
  0


Final ID: MDP1579

Circulating Levels of the Pro-Fibrotic Collagen Hormone Endotrophin are Associated with the Risk of Experiencing Major Adverse Cardiovascular Events in Individuals with Type 2 Diabetes – The Thousand & 2 Study

Abstract Body (Do not enter title and authors here): Introduction: Cardiovascular disease (CVD) complications are the leading cause of mortality in individuals with type 2 diabetes (T2D). Abnormal extracellular matrix (ECM) remodelling leads to the release of ECM protein fragments into circulation, reflecting these complications. Endotrophin, a pro-fibrotic and -inflammatory hormone, released during collagen type 6 formation, has been linked to adverse outcomes in T2D, but not previously in a long-term perspective.
Aim: To assess the 12-year prognostic value of circulating endotrophin levels, measured by PRO-C6, to predict the risk of major adverse cardiovascular events (MACE) in a large cohort of individuals with T2D.
Methods: Endotrophin levels were measured with the NordicPRO-C6™ ELISA in 909 serum samples from the Thousand & 2 study, which was initiated in 2011 and examined individuals with T2D, with and without known CVD. Clinical data were collected at baseline. Follow-up was 100% complete and performed on the 1st of May 2024 with the registration of data on MACE from the Danish national registers. The primary outcome was MACE, defined as incident events of hospital admission for ischemic heart disease, heart failure, stroke, or all-cause mortality. PRO-C6 was split into tertiles and examined for survival probability by Kaplan-Meier analysis. Univariate Cox proportional hazard regression analysis was conducted to examine the association between PRO-C6 and the risk of MACE. A multivariable Cox model was additionally conducted, adjusted for age at baseline, sex, systolic blood pressure, duration of diabetes, HbA1c, estimated glomerular filtration rate, use of statins, albuminuria status, and current or prior smoking.
Results: The baseline mean (±SD) age of the cohort was 64 (±10) years, 66% were males, mean (±SD) PRO-C6 was 11.9 (±7.01) ng/ml, the median follow-up time was 10.6 years, and number of MACE recorded was 472. The risk of experiencing MACE was significantly higher in the third tertile compared to the first and second tertile (Log-Rank p < 0.001). In the univariate Cox model, the estimated hazard ratio (HR), corresponding to a 2-fold increase of PRO-C6, was HR [95% Confidence Interval(CI)] = 2.1 [1.8-2.4], P <0.001. In the fully adjusted Cox model, PRO-C6 remained significantly associated with the risk of MACE (HR [95% CI] = 1.5 [1.2-1.8], P <0.001).
Conclusion: Elevated circulating endotrophin is associated with MACE in T2D, independent of common risk factors.
  • Laursen, Clara  ( Nordic Bioscience , Herlev , Denmark )
  • Bahrami, Hashmat  ( Steno Diabetes Center , Herlev , Denmark )
  • Martin, Emily  ( Nordic Bioscience , Herlev , Denmark )
  • Frederiksen, Peder  ( Nordic Bioscience , Herlev , Denmark )
  • Genovese, Federica  ( Nordic Bioscience , Herlev , Denmark )
  • Karsdal, Morten  ( Nordic Bioscience , Herlev , Denmark )
  • Jorgensen, Peter  ( Copenhagen University Hospital , Herlev , Denmark )
  • Rossing, Peter  ( Steno Diabetes Center , Herlev , Denmark )
  • Jensen, Magnus  ( Steno Diabetes Center , Herlev , Denmark )
  • Author Disclosures:
    Clara Laursen: DO NOT have relevant financial relationships | Hashmat Bahrami: DO NOT have relevant financial relationships | Emily Martin: No Answer | Peder Frederiksen: No Answer | Federica Genovese: DO have relevant financial relationships ; Employee:Nordic Bioscience:Active (exists now) ; Individual Stocks/Stock Options:Nordic Bioscience:Active (exists now) | Morten Karsdal: DO have relevant financial relationships ; Individual Stocks/Stock Options:Nordic Bioscience:Active (exists now) ; Employee:Nordic Bioscience:Active (exists now) | Peter Jorgensen: DO NOT have relevant financial relationships | Peter Rossing: DO have relevant financial relationships ; Research Funding (PI or named investigator):Bayer:Active (exists now) ; Speaker:novartis:Past (completed) ; Speaker:abbott:Past (completed) ; Advisor:gilead:Active (exists now) ; Advisor:boehringer ingelheim:Active (exists now) ; Advisor:bayer:Active (exists now) ; Advisor:novo nordisk:Active (exists now) ; Advisor:astra zeneca:Active (exists now) ; Research Funding (PI or named investigator):Lexicon:Active (exists now) ; Research Funding (PI or named investigator):Novo Nordisk:Active (exists now) ; Research Funding (PI or named investigator):astra zeneca:Active (exists now) | Magnus Jensen: No Answer
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

Prediction in Cardiometabolic Disease

Monday, 11/18/2024 , 12:50PM - 02:15PM

Moderated Digital Poster Session

More abstracts on this topic:
An innate immune component in hypertension-induced cardiac dysfunction
Christoph Mora, Katherine Deck, Yunmeng Liu, Lance Benson, Tonya Rafferty, & Shengyu Mu

Mora Christoph, Deck Katherine, Liu Yunmeng, Mu Shengyu, Benson Lance, Guo Yunping

Association of GLP-1 Receptor Agonist Use with Clinical Outcomes in Diabetic Patients Hospitalized for Ischemic Stroke

Viswanath Varun, Kothari Sachin, Siegler James, Coleman Elisheva, Brorson James, Prabhakaran Shyam, Mansour Ali, Kass-hout Tareq, Iourinets Julia, Jhaveri Aditya, Chahine Ahmad, Sehgal Neha, Morsi Rami, Badillo Goicoechea Elena, Thind Sonam, Desai Harsh

More abstracts from these authors:
Inhibition of Cardiac Fibrosis and Pro-Fibrotic Collagen Hormone Endotrophin by VS-041, a Novel Drug Candidate for Heart Failure with Preserved Ejection Fraction

Plonowski Artur, Berger Joel, Pratt Benjamin, Krupa Magdalena, Vekich John, Bochenek Wieslaw, Larson Christopher, Moreno Ydalina, Genovese Federica

Circulating biomarkers of collagen type-I degradation are associated with risk of mortality after ST-elevated myocardial infarction.

Martin Emily, Angeli Elisavet, Laursen Clara, Genovese Federica, Karsdal Morten, Frydland Martin, Moller Jacob, Hassager Christian

You have to be authorized to contact abstract author. Please, Login
Not Available